Scientists and medical experts from all over Europe caution that enthusiasm on the broad potential of regenerative medicine applications has led to a gap between expectations and the realities of translating regenerative medicine technologies into clinical practice. In a first-time report, the European Academies of Science (EASAC) and Medicine (FEAM) call upon European lawmakers to protect biomedical science from false claims.
“Stem cell and gene-based therapies hold great medical promises. But we are alarmed over a trend to lower requirements of evidence. Also, we can see an increasing problem of commercial clinics offering unregulated products and services,” says Prof. Volker ter Meulen, Co-chair of the EASAC-FEAM Working Group and Past President of EASAC.
Read the press release from EASAC and FEAM
Read the report Challenges and potential in regenerative medicine